Longmore 2007.

Study characteristics
Methods	Study design: longitudinal cohort Country: USA Data collection period: the PREMIER registry began on January 1st 2003 and ended on June 28th 2004 Registry ID: N/A (cohort)
Participants	Number of participants: N = 1144; Number included in meta‐analysis: N = 640 Sample characteristics (at baseline): Age (mean): participants were 18+ years; Sex (% male): not reported Population category: chronic physical conditions; Specific population: people with myocardial infarction (MI) Nicotine dependence: not reported; Baseline cigarettes per day: not reported; Motivation to quit: not selected by motivation to quit
Interventions	Behavioural support for smoking cessation: no behavioural support Pharmacological support for smoking cessation: no pharmacological support Psychotherapeutic or psychoactive support for mental health or mood: did not receive mood management
Outcomes	Definition of cessation used: quitters defined as those who were smoking at baseline but not 6‐ and 12‐months post‐MI Cessation definition used for outcome(s) in this analysis: unclear point‐prevalence Measure of biovalidation: not bioverified Definition of people who continued to smoke used: not reported Time point(s) at which follow‐up was conducted: baseline (time of MI), 6‐ and 12‐months post‐MI Outcome category: Psychological Quality of Life (QoL) Outcome measure(s): Short Form‐12 (SF‐12; mental component scale (MCS))
Funding source	This study was principally supported by CV Therapeutics, Inc, Palo Alto, CA, and R‐01 HS11282‐01 from the Agency for Healthcare Research and Quality, Rockville, MD, This study was also supported by a Veterans Affairs Health Services Research Advanced Research Career Development Award (ARCD‐98‐341‐2) (Dr Rumsfeld), Washington, DC
Author conflicts of interest	None specified
Notes	Outcome data source: Published data (conference abstract)